What Next for Cara Therapeutics, Inc. (CARA) Stock After Today’s Huge Increase?

July 11, 2018 - By Peter Erickson

Cara Therapeutics, Inc. (NASDAQ:CARA) Logo

Investors sentiment decreased to 0.83 in 2018 Q1. Its down 0.10, from 0.93 in 2017Q4. It worsened, as 13 investors sold Cara Therapeutics, Inc. shares while 27 reduced holdings. 15 funds opened positions while 18 raised stakes. 15.62 million shares or 1.17% less from 15.80 million shares in 2017Q4 were reported.
Rhumbline Advisers invested in 25,306 shares. Horrell Cap Mgmt reported 400 shares stake. The New York-based Ny State Common Retirement Fund has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Rho Cap Ptnrs Inc holds 3.57M shares or 62.3% of its portfolio. Morgan Stanley has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Voya Invest Management Ltd Liability Corporation holds 0% or 12,316 shares. Aqr Cap Mgmt Lc has 16,817 shares. Stifel Financial invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Daiwa Secs Gp Inc holds 0% in Cara Therapeutics, Inc. (NASDAQ:CARA) or 180 shares. Deutsche Bancorporation Ag owns 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 40,054 shares. Whittier Co Of Nevada Inc stated it has 423 shares or 0% of all its holdings. Davenport & Lc stated it has 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Bnp Paribas Arbitrage has 5,698 shares. Schwab Charles Invest Mngmt Incorporated accumulated 54,335 shares or 0% of the stock. Cambridge Invest Research Incorporated has invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA).

Since January 24, 2018, it had 0 insider buys, and 7 selling transactions for $778,740 activity. The insider CHALMERS DEREK T sold 12,500 shares worth $187,500.

The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) is a huge mover today! The stock increased 3.91% or $0.81 during the last trading session, reaching $21.53. About 1.12 million shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 1.86% since July 11, 2017 and is uptrending. It has underperformed by 10.71% the S&P500.
The move comes after 9 months positive chart setup for the $704.03M company. It was reported on Jul, 11 by Barchart.com. We have $23.04 PT which if reached, will make NASDAQ:CARA worth $49.28 million more.

Analysts await Cara Therapeutics, Inc. (NASDAQ:CARA) to report earnings on August, 2. They expect $-0.51 EPS, down 75.86 % or $0.22 from last year’s $-0.29 per share. After $-0.51 actual EPS reported by Cara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

Among 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 9 analyst reports since January 19, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 12. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) earned “Buy” rating by H.C. Wainwright on Monday, March 19. The company was upgraded on Monday, February 12 by Janney Capital. The rating was maintained by Laidlaw with “Buy” on Thursday, May 24. Canaccord Genuity maintained the shares of CARA in report on Thursday, March 15 with “Buy” rating. As per Friday, May 11, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Friday, June 29 by Canaccord Genuity. H.C. Wainwright maintained Cara Therapeutics, Inc. (NASDAQ:CARA) on Wednesday, May 23 with “Buy” rating.

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: Seekingalpha.com which released: “Cara Therapeutics: Scratching An Itch Left Unscratched” on June 27, 2018, also Streetinsider.com with their article: “Cara Therapeutics (CARA) Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA for Pruritus in Stage III-V …” published on July 11, 2018, Globenewswire.com published: “Factors of Influence in 2018, Key Indicators and Opportunity within Camden National, Cara Therapeutics, Albany …” on June 21, 2018. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: Fool.com and their article: “Here’s Why Cara Therapeutics Jumped 26.3% in May” published on June 14, 2018 as well as Fool.com‘s news article titled: “The Best Marijuana Stocks in the Second Quarter” with publication date: July 04, 2018.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $704.03 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.